We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The government’s response to the ACMD’s fentanyl report.
Report from the Advisory Council on the Misuse of Drugs (ACMD) on the classification and schedule of Remimazolam.
Letter to the chair of the ACMD inviting them to establish a working group to respond to the recent white paper on drug possession.
Letter from ACMD to ministers, providing advice on the administration rights of morphine by injection for therapeutic radiographer independent prescribers.
Letter from Advisory Council on the Misuse of Drugs (ACMD) to ministers, providing advice on independent prescribing of controlled drugs by paramedics.
Government response to the ACMD's advice on the prescribing of controlled drugs by paramedics and on the administration rights of morphine by injection for therapeutic radiographers.
The Advisory Council on the Misuse of Drugs (ACMD) has published a report reviewing the availability and use of naloxone in the UK, a drug used to reverse opioid overdose.
Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Minister of State for Crime Reduction and Policing on the interim podiatrists supply proposal.
Advice on preventing drug misuse among vulnerable groups of people, with a focus on understanding factors that contribute to vulnerability.
The report "Preventing drug use among vulnerable groups of people", commissioned by the Home Office, has been published by the ACMD.
Provides a summary of the main issues the ACMD considered between January 2017 and December 2019.
Provides a summary of the main issues the ACMD considered between April 2013 and December 2016.
The government commissions the ACMD to advise on the appropriate classification and scheduling of Isotonitazene and related compounds.
The government responds to the ACMD reports on cannabis-based products for medicinal use (CBPMs) in humans.
Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Minister of State for Crime Reduction and Policing on Sunosi advice.
A document developed by the Advisory Council on the Misuse of Drugs (ACMD) to outline the governing process for preparing evidence-based advice.
Barriers to Research working group calls for written evidence about barriers to legitimate research for controlled drugs, excluding synthetic cannabinoids.
Advisory Council on the Misuse of Drugs (ACMD) call for evidence on cannabinoids in CBD products.
The Advisory Council on the Misuse of Drugs (ACMD) has reappointed 4 experts in their fields to serve their third term on the council.
An assessment of the impact of rescheduling CBPMs to Schedule 2 under the Misuse of Drugs Regulations 2001 (MDR) and recommendations to mitigate the issues identified.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).